Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
European Urology Oncology|April 22, 2023
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314Yi-Tsung Lu, Melissa Plets, Gareth Morrison, et al.
BJU International|July 17, 2024
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinomaAbhishek Tripathi, Catherine M Tangen, Melissa Plets, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerSeth P Lerner, David J McConkey, Catherine M Tangen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)Michael J Wagner, Megan Othus, Sandip P Patel, et al.
European Urology|July 6, 2023
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
European Urology|July 13, 2024
Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 TrialElizabeth R Plimack, Catherine Tangen, Melissa Plets, et al.
Lancet (London, England)|February 16, 2021
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trialSumanta K Pal, Catherine Tangen, Ian M Thompson, et al.
NPJ Digital Medicine|March 23, 2025
Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learningZilong Bai, Mohamed Osman, Matthew Brendel, et al.
JAMA Network Open|October 7, 2024
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate CancerAmir Goldkorn, Catherine Tangen, Melissa Plets, et al.
Pageof 4